Home
Products
Learn
About
Pricing
Log In
IME
Asset Logo

Imexhs Limited

🇦🇺 ASX

🩺 HEALTH CARE

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

+ 356.19%
Annual Growth

5 years average annual capital growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

2
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

ImExHS Ltd. engages in the development and sale of its Hiruko software platform. The company is headquartered in Mascot, New South Wales. The company went IPO on 2005-12-14. The firm develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The firm's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.

📈 Performance

Price History

+393.75%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.40

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in IME

2

📊 Total Capital Earnings

$323.49

🔃 Average investment frequency

15 weeks

💵 Average investment amount

$632

Last time a customer invested in IME

321 days
IME investor breakdown
💵 Income of investors

More than 200k

33%

150k - 200k

100k - 150k

50k - 100k

67%

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

100%
🙋 Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in IME also invest in...

Wesfarmers Limited

WES

Wesfarmers Ltd. engages in the provision of fresh food, groceries, general merchandise, liquor, fuel, and financial services. The company is headquartered in Perth, Western Australia and currently employs 120,000 full-time employees. Its segments include Bunnings Group; Kmart Group; Officeworks; Wesfarmers Chemicals, Energy and Fertilisers (WesCEF); Industrial and Safety; Health; Catch; and Other. The Bunnings Group segment is a retailer of building materials and home, garden and lifestyle improvement products. The Kmart Group segment is a retailer of apparel and general merchandise, including toys, leisure, entertainment, home, and consumables. The Officeworks segment is a retailer and supplier of office products and solutions for households, small-to-medium sized businesses, and the education sector. The WesCEF segment is a manufacturer and marketer of chemicals for industry, mining, and mineral processing; manufacturer and marketer of broadacre and horticultural fertilizers; and others.

🙌 Performance (5Yr p.a)

22.34%

📊 Share price

$73.46 AUD

🛍️ CONSUMER

🍃 HIGH ESG SCORE

🌳 ENVIRONMENTAL

🕊️ SOCIALLY AWARE

📈 HIGH PRICE GROWTH

Find Out More

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

🙌 Performance (5Yr p.a)

13.04%

📊 Share price

$0.03 AUD

📈 HIGH PRICE GROWTH

🧬 BIOTECHNOLOGY

Audinate Group Ltd. engages in the provision of development and commercialization of audio-visual software and hardware. The Company’s principal activity is the development and sale of digital audiovisual (AV) networking solutions. Dante is its technology platform that distributes digital audio and video signals over computer networks. Dante comprises software and chips, cards and modules that are sold to and integrated inside the AV products of its original equipment manufacturer (OEM) customers. The firm also provides a series of products and services to AV professionals, including AVIO adapters and management and control software. Its Dante IP networking solution is used extensively in the professional live sound, commercial installation, broadcast, public address, and recording industries. Dante replaces traditional analogue cables by transmitting synchronized AV signals across large distances to multiple locations at once, using nothing more than an ethernet cable.

🙌 Performance (5Yr p.a)

11.39%

📊 Share price

$6.20 AUD

📈 HIGH PRICE GROWTH

🔨 COMMERCIAL SERVICES & SUPPLIES

ANZ Group Holdings Ltd. operates as a non-operating holding company. Its divisions include Australia Retail, Australia Commercial, Institutional, New Zealand, Suncorp Bank, Pacific, and Group Center. The Australia Retail division provides a full range of banking services to Australian consumers. This includes Home Loans, Deposits, Credit Cards and Personal Loans. The Australia Commercial division offers a range of banking products and financial services, including asset financing. The Institutional division services global institutional and corporate customers, and governments across Australia, New Zealand and International, including Papua New Guinea, via the business units, such as Transaction Banking, Corporate Finance, and Markets. New Zealand division comprises of business unit, such as Personal and Business & Agri. The Suncorp Bank division provides banking and related services to retail, commercial, small and medium enterprises and agribusiness customers in Australia.

🙌 Performance (5Yr p.a)

16.80%

📊 Share price

$29.48 AUD

🏦 BANKING

⚖️ HIGH GOVERNANCE

💰 HIGH DIVIDEND

📈 HIGH PRICE GROWTH

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

🙌 Performance (5Yr p.a)

23.51%

📊 Share price

$59.41 AUD

📈 HIGH PRICE GROWTH

🇺🇸 UNITED STATES

Want more shares? Try these...

IMEDB

📊 Share price

$15500.00 AUD
Compare
Add to watchlist